Immunomodulatory drugs combat MM by suppressing immune escape (25, 26) while proteasome inhibitors exert therapeutic effects through mechanisms such as inducing tumor cell apoptosis and inhibiting the NF-κB signaling pathway (27–29). This evidence concerns the gene NFKB1 and Miyoshi myopathy.